Clinical Trials Logo

Nervous System Neoplasms clinical trials

View clinical trials related to Nervous System Neoplasms.

Filter by:

NCT ID: NCT03150862 Completed - Clinical trials for Brain and Central Nervous System Tumors

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Start date: July 24, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety, efficacy and clinical activity of Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in participants with newly diagnosed or recurrent/refractory glioblastoma.

NCT ID: NCT03147989 Completed - Clinical trials for Central Nervous System Diseases

Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients

Start date: May 18, 2017
Phase:
Study type: Observational

This is a retrospective study to collect already existing data and images from patients ≥ 2 years of age who had MRI for CNS diseases with MultiHance administration at a standard 0.10 mmol/kg dose or the half dose of 0.05 mmol/kg. The MRI images of all included patients will be prospectively reviewed in a blinded read to compare the efficacy of the two doses.

NCT ID: NCT03071913 Completed - Clinical trials for Metastatic Malignant Neoplasm in the Brain

Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery

Start date: September 20, 2017
Phase:
Study type: Observational

This pilot research trial studies blood brain barrier differences in patients with brain tumors undergoing surgery. Studying samples of tissue and blood from patients with brain tumors in the laboratory may help doctors to understand how well drugs get into different parts of a brain tumor. This may help them to determine which types of drugs may be best for treating brain tumors.

NCT ID: NCT03012620 Completed - Sarcoma Clinical Trials

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

AcSé
Start date: July 5, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of pembrolizumab monotherapy in 7 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available, in order to identify subsets of patients that may benefit from treatment

NCT ID: NCT02808650 Completed - Clinical trials for Refractory Malignant Solid Neoplasm

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Start date: February 27, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond to treatment. Checkpoint kinase 1 inhibitor LY2606368 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02793466 Completed - Lymphoma Clinical Trials

Durvalumab in Pediatric and Adolescent Patients

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This clinical trial is the first clinical trial to study Durvalumab, a checkpoint inhibitor which stimulates the patient's own immune system to act against cancer cells in children and adolescents. This trial will assess the safety and tolerability of Durvalumab in children and adolescents and also study how Durvalumab is processed in their bodies.

NCT ID: NCT02780804 Completed - Clinical trials for Refractory Malignant Solid Neoplasm

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Start date: January 6, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.

NCT ID: NCT02710240 Completed - Clinical trials for Suspected Central Nervous System Tumors

Indocyanine Green for Central Nervous System Tumors

Start date: June 10, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single center, open-label, two-part study to assess image guided surgery of intramolecular imaging in nervous system tumors. Subjects with a diagnosis of a resectable nervous system tumor who are at risk of recurrence are included. The primary goal is to observe what tissues fluoresce in the OR, and then to identify if that tissue is cancerous/tumor or normal when the histopathology is performed.

NCT ID: NCT02496520 Completed - Sarcoma Clinical Trials

Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults

DEND/TIA
Start date: September 30, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II, open, prospective clinical trial, historically controlled. The objective is to evaluate the safety and, as a secondary measure, the efficacy of an experimental treatment based on a cellular therapy (vaccination with autologous dendritic cells pulsed with tumor lysate) in patients affected of metastatic or relapsed sarcomas or (Central Nervous System) CNS tumors.

NCT ID: NCT02462629 Completed - Clinical trials for Central Nervous System Tumors

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

Start date: June 2015
Phase: Phase 1
Study type: Interventional

Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in pediatric patients with central nervous system tumors.